Abstract Recent studies have identified a role for supraphysiological gamma-aminobutyric acid (GABA) in the regulation of mechanistic target of rapamycin (mTOR), a protein kinase with pleiotropic roles in cellular development and homeostasis, including integration of growth factors and nutrient sensing and synaptic input in neurons (Lakhani et al. 2014; Vogel et al. 2015) . Aldehyde dehydrogenase 5a1-deficient (aldh5a1
) mice, the murine orthologue of human succinic semialdehyde dehydrogenase deficiency (SSADHD), manifest increased GABA that disrupts mitophagy and increases mitochondria number with enhanced oxidant stress. Treatment with the mTOR inhibitor, rapamycin, significantly attenuates these GABA-related anomalies. We extend those studies through characterization of additional rapamycin analog (rapalog) agents including temsirolimus, dual mTOR inhibitors [Torin 1 and 2 (Tor 1/ Tor 2), , as well as mTORindependent autophagy inducers [trehalose, , and NF-449) in aldh5a1 -/-mice. Rapamycin, Tor 1, and Tor 2 rescued these mice from premature lethality associated with status epilepticus. XL-765 extended lifespan significantly and induced weight gain in aldh5a1 -/-mice; untreated aldh5a1 -/-mice failed to increase body mass. Expression profiling of animals rescued with Tor 1/Tor 2 and XL-765 revealed multiple instances of pharmacological compensation and/or correction of GABAergic and glutamatergic receptors, GABA/glutamate transporters, and GABA/glutamate-associated proteins, with Tor 2 and XL-765 showing optimal outcomes. Our studies lay the groundwork for further evaluation of mTOR inhibitors in aldh5a1 -/-mice, with therapeutic ramifications for heritable disorders of GABA and glutamate neurotransmission.
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Introduction
The inhibitory neurotransmitter gamma-aminobutyric acid (GABA) derives from excitatory glutamate via the catalytic action of glutamate decarboxylase (GAD). Subsequently, GABA converts to succinic acid via the sequential actions of aminobutyrate aminotransferase (ABAT) and succinic semialdehyde dehydrogenase (ALDH5A1); aldehyde dehydrogenase 5a1 = succinic semialdehyde dehydrogenase (SSADH). Mendelian disorders of each catabolic enzyme exist Lapalme-Remis et al. 2015; Rodan et al. 2015) . SSADHD presents with nonspecific mild to moderate developmental delay, severe expressive language impairment, variable epilepsy Pearl et al. 2014) , and
Communicated by: Niels Gregersen * Kara R. Vogel k.vogel@wsu.edu neuropsychiatric problems [i.e., attention deficit hyperactivity disorder (ADHD), obsessive compulsive disorder (OCD), aggression]. Metabolically, there is accumulation of glutamate, GABA, and the GABA-derivative gamma-hydroxybutyrate (GHB) (Snead and Gibson 2005) , the latter an intermediate with a varied and complex pharmacological history (Maitre et al. 2016) (Fig. 1) . Although historically considered a central nervous system (CNS) inhibitory neurotransmitter, a growing literature underscores broader implications for GABA in peripheral roles, as well as in mTOR signaling. mTOR regulates cellular development and homeostasis, including integration of growth factors and nutrient sensing, and synaptic input in neurons (Lafourcade et al. 2013; Santinon et al. 2015; Han et al. 2016) . For example, mTOR mediates synaptic regulation by modulating synapse number and miniature inhibitory postsynaptic currents (Weston et al. 2012a ). Hyperactive mTOR increases evoked synaptic responses in both glutamatergic and GABAergic neurons, and the glutamatergic component is corrected by the mTOR inhibitor rapamycin. Workman and colleagues demonstrated that GABA B receptors can activate mTOR via calcium signaling and further demonstrated that signaling of the GABA B receptor was necessary for mTORdependent protein synthesis (Workman et al. 2013) . These publications highlight the complex synergy that appears to exist between GABA and mTOR.
Lakhani and coworkers recently identified a novel relationship between GABA and autophagy in yeast in which elevated GABA impaired both mitophagy and pexophagy (Lakhani et al. 2014) . These findings were extended to the aldh5a1 -/-mouse, a model for which intervention with rapamycin resulted in a significant mitigation of hepatic elevations of pS6 (a kinase linked to mTOR function), superoxide dismutase (SOD), and mitochondrial number. Comparable impairments of autophagy have recently been documented for vigabatrin, an antiepileptic agent that irreversibly inactivates ABAT and elevates GABA (Vogel et al. 2015) . Accordingly, the mTOR pathway appears to be a viable therapeutic target for disorders featuring dysregulated GABA homeostasis. To further explore this hypothesis, we examined the effect of various modulators of mTOR and autophagy in aldh5a1 -/-mice to further interrogate the preclinical efficacy of this approach. Here, we summarize the outcomes of our studies.
Methods
Reagents and drugs
Rapamycin, Torin 1, Torin 2, temsirolimus, XL-765, , and NF-449 were purchased from Cayman Chemical (Ann Arbor, MI, USA) and prepared in dimethyl sulfoxide (DMSO) at 25 mg/ml. Trehalose was obtained from Sigma Aldrich (St. Louis, MO, USA) and prepared in DMSO at 250 mg/ml. Tat-Beclin 1(tat-Bec1) human recombinant peptide was purchased from EMD Millipore (Billerica, MA, USA) and prepared at concentrations of 25 and 125 mg/ml. Cell-culture-grade DMSO was obtained from Thermo Fisher (Waltham, MA, USA).
Animal studies
All animal procedures were approved by the Washington State University Institutional Animal Care and Use Committee Fig. 1 Interrelationships of gamma-aminobutyric acid (GABA) metabolism. Arrows (downward/upward) indicate the direction of metabolite disruption in aldehyde dehydrogenase 5a1 (aldh5a1) -/-mice. Vigabatrin (VGB), an antiepileptic and irreversible inhibitor of GABA-T, is a frequently employed therapeutic agent for SSADHD. Gln glutamine, Glu glutamate, GABA gamma-aminobutyrate, SSA succinic semialdehyde, GHB gamma-hydroxybutyrate, mTOR mechanistic target of rapamycin, GAD glutamic acid decarboxylase, GABA-T GABAtransaminase, SSR succinic semialdehyde reductase, GHBDH gammahydroxybutyrate dehydrogenase, SSADH succinic semialdehyde dehydrogenase (site of the defect in patients with SSADH deficiency (SSADHD), GLS glutamate synthetase, GS glutaminase (IACUC) (protocols 4232 and 4276). Tail biopsy of aldh5a1 mice was performed at day of life (DOL) 10-12, followed by DNA extraction and genotyping by 3 primer 2 reaction polymerase chain reaction (PCR) (Hogema et al. 2001 ). This procedure was repeated at the conclusion of survival studies in order to confirm genotype. For drug treatment, stock solutions were diluted in phosphate-buffered saline (PBS) based on body weight to a total injection volume of 50 μl. Intraperitoneal injections were given daily between 0700 and 1000 h. Rapamycin, Tor 1, Tor 2, temsirolimus, XL-765, Ku-0063794, and FK-506 were administered at 5 mg/ kg per day; Tor 2 was also further characterized at 10 mg/kg per day. Tat-Bec1 was evaluated at 5 and 25 mg/kg per day and trehalose at 100 mg/kg per day. Large litters of mice were culled to less than six pups after completion of the first round of genotyping. At weaning (21 days of age), mice were housed with one or two identical gender litter mates (not singly). Kaplan-Meier plots of survival data were generated with GraphPad Prism 6, which computed survival proportions and log-rank (Mantel-Cox) test p values, with 0.05 set as the threshold for significance.
Expression studies
RNA was prepared by pooling liver or brain tissues with four for wild-type (Wt) and mutant (Mt) mice, DOL 21; two survivors for Tor 1 (DOL 50); one survivor each for 5 mg/kg Tor 2, tat-Bec1, and XL-765 (DOL 50); and homogenized with TRIzol® (Invitrogen). The aldh5a1 -/-model demonstrates uniform lethality by DOL 24 from status epilepticus (Hogema et al. 2001; Gupta et al. 2002) , such that survival to DOL 50 is highly significant. Chloroform was added to pooled tissues, and samples were separated by centrifugation to isolate the RNA-enriched aqueous supernatant. RNA was subsequently precipitated and washed with isopropanol and ethanol, followed by brief air drying and reconstitution in water. RNA was quantified via absorbance (260 nm) and purity assessed using 260 nm/280 nm absorbance ratio (>1.8), with storage at −80°C. iScript mastermix (Biorad, Hercules, CA, USA) was employed to generate complementary DNA (cDNA) in an Eppendorf mastercycler per manual instructions. Sybr green (Biorad) reactions (10 μl) were loaded with 50 ng of cDNA/well into prearrayed and validated per Minimum Information for Publication of Quantitative Real-time PCR Experiments (MIQE) guidelines (Bustin et al. 2009 ), GABA/glutamate analysis plates (M394 PrimePCR TM , SABioscience target list). A BioRad CFX384 real-time PCR operated with BioRad CFX manager v3.0 software was employed for data acquisition, normalization, expression, and statistical analysis, with significance set at 0.05 based upon two replicates per group.
Results
Rescue of aldh5a1 -/-mice from premature lethality: mTOR and dual inhibitors of autophagy
Ald5ha1
-/-mice (mixed gender) provided baseline data, with survival to a maximum of 25 days (n = 12, 50 % at 17 days). Rapamycin, the classic mTOR complex 1 (mTORC1) inhibitor, extended lifespan of three aldh5a1 -/-mice to 42, 45, and 47 days (n = 6, 50 % survival to 23 days, 5 mg/kg body weight, p = 0.0327). Temsirolimus, a next-generation mTORC1 inhibitor with improved bioavailability, extended lifespan of one mouse to 50 days (n = 8, 50 % survival at 22-23 days, 5 mg/kg, p = ns) (Fig. 2) . Tor 1, Tor 2, and Ku-0063794 inhibit both complexes of mTOR, mTORC1, and mTORC2. Tor 1 extended lifespan for two aldh5a1 -/-mice ) mice. Top mechanistic target of rapamycin (mTOR) inhibitors; middle mTOR-independent inhibitors of autophagy; bottom mixed (dual) mTOR inhibitors. P values correspond to overall data plotted on each pane for each class of inhibitor. For drug-specific statistical evaluations, please see text to 50 days of life (n = 4, 50 % survival to 26 days, 5 mg/kg dose, p = 0.0116). Adverse effects observed in aldh5a1 -/-mice with Tor 1 included development of fibrotic tissue at the injection site, ataxia, and distended limbs. Tor 2 manifested none of these side effects. Tor 2 extended lifespan of aldh5a1 -/-mice, including one mouse at the 5 mg/kg dose (n = 8, 50 % survival to 19-20 days, p = ns) and two mice at 10 mg/kg (n = 5, 50 % survival to 25 days, p = 0.0074). Ku-0063794 had no effect on longevity of aldh5a1 -/-mice (n = 8, 50 % survival to 22 days, 5 mg/kg, p = ns). Aldh5a1 -/-mice are essentially static for, or lose, body weight from 2 weeks of age until expiration (Gupta et al. 2002; Nylen et al. 2008a) . XL-765 is a potent dual inhibitor of PI3K and mTOR known to permeate the blood-brain barrier, and its use resulted in extended survival and modest improvement in body weight of aldh5a1 -/-mice out to 50 days (n = 4, 40 % survival to 37 days, 5 mg/kg, p = 0.0194*.
Rescue of aldh5a1
-/-mice from premature lethality: mTOR-independent inducers of autophagy FK-506 , an inhibitor of calcineurin and an mTORindependent inducer of autophagy, extended lifespan of aldh5a1 -/-mice up to 23 days (n = 4, 75 % survival to 20 days, 5 mg/kg, p = ns). NF-449, a suramin analog and purinergic receptor P2X 1 (P2X1) inhibitor, induces autophagy through impaired binding of the G protein G sα-s . NF-449 did not extend lifespan (n = 5, 60 % survival to 22 days, 5 mg/kg, p = ns). Trehalose, a disaccharide that induces autophagy independent of mTOR, extended the lifespan of aldh5a1 -/-mice up to 23 days of life (n = 4, 50 % survival to 21-22 days, 100 mg/kg, p = ns). Tat-Bec1, an autophagyinducing peptide potentially acting through Golgiassociated plant pathogenesis-related protein (GAPR-1) (Shoji-Kawata et al. 2013) , extended the lifespan of one aldh5a1 -/-mouse to 50 days (n = 5, 50 % survival to 17-20 days, 5 mg/kg, p = ns) and one aldh5a1 -/-mouse to 47 days of life (n = 4, 50 % survival to 20 days, 25 mg/kg, p = ns) (Fig. 2) .
Improved body weight in aldh5a1 -/-mice via mTOR
In addition to early lethality, aldh5a1 -/-mice are runted and essentially show little capacity for weight gain from birth until death. The only effective mechanism thus far for induction of weight gain in this animal has been the ketogenic diet (Nylen et al. 2008a ). In our study, we monitored weight gain as a function of drug intake (Fig. 3) . Figure 3 presents body mass for the longest-lived individual mouse as a function of drug intervention. In our hands, weight gain (best to worst) revealed the following trend: XL-765 > Tor 1 ∼ Tor 2 ∼ tatBec1 > rapamycin.
Gene-expression profiling
We assessed the pharmacologic effects of Tor 1/Tor 2, XL-765, and tat-Bec1 on GABA and glutamate receptor subunits and transporters, as well as GABA-and glutamate-related enzymes and proteins, in the brain. The pooled tissues represented four each untreated aldh5a1 +/+ mice and untreated aldh5a1 -/-animals (DOL 21), two Tor 1-treated aldh5a1 -/-mice, and one each Tor 2-, XL-765-, and tat-Bec1-treated aldh5a1 -/-animals. Statistical analysis for the arrays employed a one-way analysis of variance (ANOVA) with post hoc Bonferroni t-test correction. Aldh5a1 -/-mice (treated or untreated) were compared with the expression level detected for untreated, control aldh5a1 +/+ mice (expression set to 1.0). We initially focused attention on GABA receptor subunits and transporters (both vesicular and nonvesicular; Fig. 4 ). As predicted, for all subunits and transporters, expression direction was down-regulation in untreated aldh5a1 -/-mice, expected with use-dependent effects of elevated GABA. Intervention with Tor 1 alone led to correction of Gabrb1 and Gabrg expression level. Tor 2, XL-765 and tat-Bec1 were effective in leading to correction of subunit expression, normalizing the levels of Gabrb3, Gabre, Slc32a1 and Slc6a11. Both Tor 1 and Tor 2 resulted in the correction of Gabra1, Gabra2 and Slc6a12 expression. Tor 1, XL-765, and tat-Bec1 normalized Gabbr1, and XL-765 and tat-Bec1 also normalized Gabbr2. It was of interest that Tor 2 did not correct GABA B receptor (metabotropic) anomalies, while numerous corrections of GABA A receptors (ionotropic) were observed.
We next turned our attention to glutamate receptors and transporters. The former included kainate, N-methyl D-aspartate (NMDA), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and metabotropic glutamate receptors (mGLUR), while the latter included both vesicular glutamate and excitatory amino acid transporters (Fig. 5) . As was the case for GABA receptor subunits and transporters, the direction for expression in untreated aldh5a1 -/-mice was down-regulation, as expected, since glutamate is also elevated in this model (Gupta et al. 2004 ). The sole exception was the up-regulation of the transporter solute carrier family 7 member 11 (Slc7a11) (Fig. 5) . Intervention with Tor 1 corrected the expression of Gria3, Grik5, Grin2b, and Slc1a1. Intervention with Tor 2 resulted in the corrected expression of Gria1, Grm7, Slc17a6, Slc17a8, and Slc38a1. Both interventions lead to the correction of Gria2, Gria4, Grik2, Grin2b, Grin2c, Grm1, Grm2, Grm4, Grm5, Grm8, and Slc1a2. XL-765 corrected Grin2b, Grm1, Grm2, Grm5, Slc17a6, Slc17a8, Slc1a1, Slc1a2, and Slc38a1. Tat-Bec1 corrected Grik5, Grin2b, Grm1, Grm6, Slc17a6, Slc17a8, and Slc1a2.
Finally, we extended the preceding studies to include GABAand glutamate-related enzymes and proteins (Fig. 6) . As for the GABA and glutamate receptors and transporters, the direction of expression in untreated aldh5a1 -/-mice was down-regulation, with only a single instance of upregulation [beta-2 microglobulin(B2M)]. Tor 2 corrected the aberrant expression of App, Cln3, Gls, Glul, Nsf, and Snca (see Fig. 6 for full names). Tor 1 corrected the aberrant expression of beta-2 microglobulin (B2M.). All treatments (Tor 1, Tor 2, XL-765, and tatBec1) corrected Abat, Cln3, Gad1, Gls, Glul, Gphn, Hsp90ab1, Nsf, Pla2g6, and Srr. In some instances, the relationship of these genes to GABA/glutamate metabolism is readily apparent [e.g., Gls (glutamate synthetase), Glul (glutaminase) Abat aminobutyrate aminotransferase (GABA-transaminase), Gad1 (glutamic acid decarboxylase)], but the relationship of other genes is not immediately obvious. 
Discussion
This report expands the link between supraphysiological GABA and mTOR signaling described in earlier studies (Lakhani et al. 2014; Vogel et al. 2015) . Until now, drugs that have extended the lifespan of aldh5a1 -/-mice have included taurine, vigabatrin (an irreversible inhibitor of GABA-transaminase), CGP-35348 (a GABA B receptor antagonist), NCS-382 (a GHB receptor antagonist), and the ketogenic diet (Hogema et al. 2001; Gupta et al. 2002; Nylen et al. 2008a) . With the exception of taurine and the ketogenic diet, all target either GABA metabolism or GABAergic/GHBergic neurotransmission. Taurine was evaluated because of its high content in dams' milk associated with premature lethality of ald5ha1 -/-mice in the weaning period. Taurine also possesses diffuse GABA A and GABA B receptor modulatory effects (Gupta et al. 2002 ). An open-label trial of taurine in SSADHD patients was, however, without clinical benefit . Here, we present new evidence of attenuation of premature lethality in our murine model using mTOR inhibitors, supported by expression array data on GABAergic/glutamatergic systems revealing pharmacological correction with mTOR inhibitors (Donarum et al. 2006) .
We found Tor 2, XL-765, and tat-Bec1 to be optimal therapeutic agents for aldh5a1 -/-mice and that dual inhibition of mTORC1/2 was more effective than mTORC1 inhibition alone. Similar outcomes for survival occurred for tat-Bec1, emphasizing the importance of autophagy activation in the aldh5a1 -/-mice. Tat-Bec1, not to be confused with exogenous beclin 1, which is an inducer of apoptosis and autophagy (Kang et al. 2011) , was the only mTOR-independent autophagy inducer tested (including trehalose, tat-Bec1, FK-506, and NF-449) that increased survival. Similarity of the expression profiles between the dual mTORC inhibitors (Tor 2, XL-765) and tat-Bec1 may be related to the feedback mechanism between autophagy and mTOR and inhibitory effects on mTOR during autophagy initiation by the tat-Bec 1 peptide. The adverse effect profile for Tor 1 was substantial, even with multiple gene expression corrections (Figs. 4, 5 and 6 ). In our hands, these three treatments (Tor 2, XL-765, tat-Bec 1) had no visible effects on the aldh5a1 -/-phenotype other than the expected neurological morbidity normally encountered (mild ataxia). Substantial metabolic and neurophysiological data, from our laboratory and others, has previously documented disruptions of the glutamate/glutamine/GABA axis in aldh5a1 -/-mice, in addition to abnormalities of GABA A and GABA B receptors. Early metabolic studies verified elevations of GHB, GABA, and glutamate (Gupta et al. 2002 ; Figure 7 provides a schematic that clarifies the role of these genes/receptors/enzymes (putative and proven) in both glutamatergic and GABAergic signaling Gupta et al. 2004) , which correlated with alterations of glutamate/glutamine cycling in the CNS (Chowdhury et al. 2007 ). Neurophysiological and neurochemical characterization of aldh5a1 -/-mice verified central, as well as localized (hippocampal, cortical), disruption of GABAergic neurotransmission that manifested as down-regulated GABA B and GABA A receptors (Cortez et al. 2004; Wu et al. 2006; Buzzi et al. 2006; Drasbek et al. 2008; Dósa et al. 2010; Vardya et al. 2010; Errington et al. 2011) . Data in mice have been confirmed in SSADHD patients using transcranial magnetic stimulation for GABA B receptors (Reis et al. 2012 ) and 11 Cflumazenil binding for GABA A receptors (Pearl et al. 2009 ), as well as magnetic resonance spectroscopy (Ethofer et al. 2004; Wang et al. 2015) with spectral editing for GABA and Glx (glutamine and glutamate combined). Our results, indicating significant down-regulation of receptor subunits and transporters, is consistent with the mouse and human neurophysiological/neurochemical data, but the pharmacological compensation with mTOR inhibitors is quite novel and clinically relevant (Figs. 4-6 ).
An exciting finding in our study was the effect of Tor 1 and Tor 2 on glutamatergic systems (Fig. 5) , which was unexpected despite our previous demonstration of glutamate increase in the CNS of aldh5a1 -/-mice (Gupta et al. 2004) . A link between glutamatergic signaling and mTOR activation is beginning to emerge (Weston et al. 2012a; Theilhaber et al. 2013; Chen Fig. 7 Interrelationships of glial-cell function with that of glutamatergic and gamma-aminobutyric acid (GABA)ergic synapses. The roles of Aldh5a1 (localized to the mitochondria, not shown), Abat (4-aminobutyrate aminotransferase), Gad1 (glutamate decarboxylase 1), Gls (glutaminase), and Glul (ferredoxin-dependent glutamate synthase 1) are recognizable. Other genes characterized in array expression (Fig. 6 ) data and the role(s) of which are less readily apparent in glialneuronal signaling include (circled in the figure): Adora2a (adenosine A2A receptor), a heteroreceptor modulating glutamate/GABA release; App (amyloid beta precursor protein), a soluble oligomeric protein interacting with N-methyl D-aspartate (NMDA) receptors; Avp (arginine vasopressin), a hormone active in stimulation of regional GABAergic neurons; Cln3 (ceroid lipofuscinosis 3), a gene shown to perturb glutamine and glutamate levels in cortex and cerebellum; Gphn (gephyrin), a scaffold protein stabilizing GABA A receptors; Itpr1 (inositol 1,4,5-trisphosphate receptor 1), a phospholipase receptor with interactions targeting the metabotropic glutamate receptor (mGluR); Nsf (Nethylmaleimide-sensitive factor), a protein interacting with α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type glutamate receptors; Pla2g6 (phospholipase A2 group VI), one of multiple phospholipases regulating the release of aspartate, glutamate, glycine, and GABA; Snca (synuclein alpha), a secreted protein interacting with adenosine triphosphate (ATP)-sensitive potassium channels modulating GABA transmission; and Srr (serine racemase), an activator of NMDA receptors. Not shown are β-2-microglobulin (B2M) and heat-shock protein 90 kDa alpha class B member 1 (Hsp90ab1), both of which may exert chaperonetype roles in scaffolding of oligomeric glutamatergic and GABAergic receptors. Post-synaptic receptors are shown in boxes. Additional abbreviations: EAAT excitatory amino acid transporter, GAT GABAtransporter, GLUT glutamine transporter Rosenberg et al. 2015) . These observations are relevant to aldh5a1 -/-embryonic mice, in which neurotransmitter imbalances are evident as early as E13, a developmental period in which GABAergic neurotransmission is still excitatory, with the potential for development of a heightened excitatory state that may predispose neural networks to epilepsy in the embryonic period (Jansen et al. 2008) . Our results for pharmacological compensation of glutamatergic systems with Tor 1 and Tor 2 suggest it will be worthwhile to investigate glutamatergic neurophysiology in aldh5a1 -/-mice as a readout of treatment efficacy, an area that has been underexplored in this animal model.
We found that mTOR-independent activators of autophagy were far less effective in the rescue of aldh5a1 -/-mice from premature lethality (Fig. 2) , with the exception of tat-Bec1. Conversely, dual mTOR pathway inhibitors appeared to be superior to mTOR complex 1 (mTORC1) inhibitors in facilitating weight gain and longevity (Fig. 3) . Moreover, data in Fig. 6 were of interest with respect to broader pathway compensation for aldh5a1 -/-mice treated with Tor 1 and 2, revealing robust correction of the down-regulated expression of Abat, Gad1, Gls, and Glul (Fig. 6) . The relationship(s) of many of the GABA-and glutamate-associated proteins and genes to GABAergic/glutamatergic signaling is schematically diagrammed in Fig. 7 . Two genes quantified in the array data of Fig. 6 were of additional interest. The down-regulation of both Adora2a and arginine vasopressin (Avp) were significantly exacerbated in Tor 1 animals by ∼ 50-to 60-fold. The adenosine A2A receptor (Adora2a) broadly functions in GABA and glutamate release (heteroreceptors), while Avp is the precursor of antidiuretic hormone (Vaz et al. 2015) . This observation in the Tor 1 group on Avp may have underpinned some of the adverse effects we observed with this mTORC1/2 inhibitor. Nevertheless, these two results would strengthen the argument for not using Tor 1 intervention in aldh5a1 -/-mice. It is of interest that the accumulation of GABA in both aldh5a1 -/-mice alters arginine metabolism and induces accumulation of guanidinobutyrate and guanidinoacetate (Jansen et al. 2006) , which may provide some insight into alterations of Avp expression.
In summary, the results presented provide evidence for pharmacological compensation of GABAergic/glutamatergic networks in aldh5a1 -/-mice treated with the mTOR inhibitors Tor 1 and Tor 2. The clinical relevance of these findings for treatment of SSADHD are significant, since it is likely that multiple treatment approaches will be needed to gain incremental improvements in the phenotype. Nonetheless, the potential of mTOR inhibitors to compensate transcriptional abnormalities in central GABAergic/glutamatergic pathways is an attractive consideration in the therapeutics of SSADHD. The translational relevance of this finding is high, since mTOR inhibitors (primarily rapamycin and temsirolimus) are actively under study in clinical trials (www.clinicaltrials. gov). More broadly, our data supports consideration of mTOR inhibitors in other Mendelian disorders, including GABAtransaminase deficiency , an expanding disorder of GABA metabolism, as well as disorders of glutamate receptors (Morice et al. 2013; Soto et al. 2014) . Future studies in aldh5a1 -/-mice will further gauge correction of the phenotype of aldh5a1 -/-mice with mTOR inhibitors using electrocorticographic assessment (Cortez et al. 2004) . These efforts will likely include more complete metabolic profiling of key metabolites (e.g., GABA, SSA, succinate, γ-hydroxybutyrate) as well as further evaluation of candidate clinical biomarkers.
